Articles related to PRECLINICAL RESEARCH

An engineered probiotic strain delivering a modified IL-2 therapy directly within pancreatic tumors slowed tumor growth and enhanced immune activity in preclinical models. Combination studies with chemotherapy, radiotherapy, and immunotherapy showed additional activity, though human data are not yet available.

Differences in cerebrospinal fluid proteins distinguished women with multiple sclerosis from age-matched controls in a small exploratory study, highlighting potential hormonal and immune-related biological mechanisms. Findings require validation in larger populations before clinical application.

FcγRIII-mediated macrophage phagocytosis emerges as the dominant mechanism of platelet destruction in FNAIT, suggesting targeted receptor blockade could offer a future therapeutic approach, though evidence remains preclinical.

Statin exposure in LPS-primed mouse muscle cells activated NLRP3 inflammasome signaling and reduced protein prenylation, producing atrophy markers and grip strength loss in a preclinical model of statin myopathy.

Erucamide, a naturally occurring lipid molecule, declined as photoreceptors deteriorated in preclinical retinal degeneration models, and restoring it via nanoparticle delivery slowed aspects of tissue breakdown without reversing damage.

Synthetic DNA molecules known as polypurine reverse Hoogsteen hairpins reduced PCSK9 expression and lowered LDL cholesterol by approximately 50% in preclinical models, representing an early-stage gene-targeted approach distinct from existing monoclonal antibody and RNA interference strategies.